23 results about "Appetite Suppression" patented technology

The application discloses application of O-acyl-alpha-hydroxy acid compounds in weight loss and lipid reduction, and belongs to the fields of biological medicine manufacturing, biological medicine use and functional food development. The O-acyl-alpha-hydroxy acid compounds can inhibit weight growth of high-fat diet-induced obese model mice and reduce body fat. Compared with GLP-1 receptor weight loss drugs which achieve the effect of reducing weight by inhibiting appetite, the O-acyl-alpha-hydroxy acid compounds are not dependent on appetite inhibition, and can reduce side effects such as gastrointestinal discomfort and muscle loss caused by inhibiting appetite. When combined or sequentially administered with GLP-1 drugs, the O-acyl-alpha-hydroxy acid compounds can maintain or enhance the weight loss effect while improving the side effects caused by GLP-1, and can prevent the risk of significant weight rebound after stopping GLP-1 by maintaining body weight. The application provides a safe and effective new strategy for weight loss and lipid reduction.

The invention provides a process for preparing a plasticised superporous hydrogel material comprising subjecting initial hydrogel material to treatment with an acidic solution, an optional treatment with a monovalent metal salt solution, freeze drying and plasticisation. Optionally, the process of the invention produces moulded plasticised superporous hydrogel material bodies that have one or more through-holes formed therein. The plasticised superporous hydrogel material of the present invention may be formulated as a suitable oral dosage form for use an appetite suppressant and for use to deliver a pharmaceutical and / or nutraceutical into a human or animal body.

The present invention discloses a guarana extract – EGCG synergistic fat-burning composition, belonging to the technical field of functional foods and weight management. The composition comprises guarana extract, epigallocatechin gallate, and konjac glucomannan. By controlling the component ratio and key parameters, a dynamic gel network formed by konjac glucomannan provides in-situ protection of active ingredients and enables programmed release in the gastrointestinal tract, while constructing a multi-level appetite-suppression system with temporal continuity.The invention overcomes problems in the prior art, including poor stability, low bioavailability, and fragmented appetite regulation, and achieves synergistic effects in fat burning and intake control. It is suitable for preparing oral solid formulations, with high safety, good stability, and suitability for large-scale industrial production and commercialization.

The present application relates to the technical field of bioactive peptides, and in particular to an oat oligopeptide, preparation thereof and application thereof in preparing a product for regulating the expression of brain appetite suppressor factor. The oat oligopeptide can effectively stimulate the release of cholecystokinin (CCK) from intestinal endocrine cells, and stimulate the central nervous system through the vagus nerve pathway, thereby promoting the expression of the appetite suppressor factor pro-opiomelanocortin (POMC) in the hypothalamus. Compared with the prior art, the oat oligopeptide has the advantages of stable structure, high safety, simple preparation process (conventional enzymatic hydrolysis and chromatographic purification can achieve the preparation), easy scale production and the like. The oat oligopeptide is suitable for being used as a functional ingredient or a drug precursor to develop a related health product with the functions of regulating appetite and promoting satiety, and has a wide application prospect in the field of preparing functional products (food, medicine and the like).

A composition comprising a soy protein isolate, a soy fibre, a phospholipid, and a carbohydrate for use in the treatment or prevention of obesity, type 2 diabetes or cardiovascular disorders, wherein the composition is administered together with a first pharmaceutical composition comprising an appetite suppressant agent.

The invention relates to the technical field of medicines, in particular to combined application of semeglutide and sodium butyrate in preparation of a medicine for reducing weight. Experimental results show that when the semeglutide and the sodium butyrate are combined for use, the appetite inhibition effect can be synergistically enhanced, and the body weight and the fat weight of a mouse are remarkably reduced.

The present application provides a soluble dietary fiber composition, its preparation method and application. After the soluble dietary fiber composition enters the colon, the ester bond in the alanine modified pectin is rapidly degraded, part of the chlorogenic acid is released, the secretion of anorectic hormone is stimulated, the appetite is reduced, and the heat intake is reduced; the remaining amide bond network is slowly degraded, realizing the slow and continuous release of chlorogenic acid. Lutein removes free radicals generated by fat decomposition, reducing the oxidative damage of L cells. Galactomannan and alanine modified pectin-glucan modified protein-chlorogenic acid ternary complex synergize to improve the molar ratio of butyric acid / propionic acid: propionic acid enhances satiety through intestinal gluconeogenesis, and butyric acid stimulates the secretion of GLP-1 / PYY, realizing endogenous appetite suppression. Galactomannan absorbs water to form a lubricating gel, softening the stool and increasing the stool volume; the ternary complex degrades to produce short-chain fatty acids, optimizing the intestinal microenvironment and enhancing gastrointestinal peristalsis, both of which synergistically improve constipation.

The present disclosure provides recombinantly manufactured fusion proteins comprising a GLP-1 protein fragment or an analog thereof linked to a feline Fc fragment. Embodiments include the administration of the fusion proteins to patients and their use as an appetite suppressant, for treatment of obesity, for prevention of obesity, or for treatment of other conditions associated with excess weight in cats. Exemplary Fc fusion proteins and pharmaceutical formulations of exemplary Fc fusion proteins are provided, in addition to methods of use and preparation.

The invention discloses application of 2-hydroxy-3-methylpentanoic acid in weight reduction and lipid reduction, and belongs to the fields of biological medicine manufacturing, biological medicine application and functional food development. The invention provides the application of the 2-hydroxy-3-methylvaleric acid and the derivative thereof in weight loss for the first time, and the compound can inhibit weight gain of a high-fat diet induced obesity model mouse, reduce body fat and reduce the fat cell area of the high-fat diet induced obesity model mouse. Compared with a GLP-1 receptor weight-reducing drug for reducing weight by inhibiting appetite, the compound 2-hydroxy-3-methylvaleric acid and the derivative thereof do not depend on appetite inhibition, and interfere and prevent obesity by accelerating fat metabolism, so that the effect of reducing weight is achieved; and side effects such as gastrointestinal discomfort and cardiovascular risk caused by appetite intervention are avoided. The invention provides a safe and effective new strategy for reducing weight and lipid.

Disclosed herein is the use of N6-benzylaminopurine (BAP) as an appetite suppressant in animals including humans. The results of studies demonstrate the use of BAP as an appetite suppressant in animals, and the use of this common agricultural supplement for plant growth can be used to help to alleviate the ever-growing obesity pandemic afflicting modern society.

The present invention aims to provide a food (including foods for specified health uses and foods with functional claims) or pharmaceutical product containing rare sugars as an active ingredient that can be used for novel applications. [Solution] The above problem is achieved by a food composition or pharmaceutical composition containing D-allose, D-sorbose, or derivatives thereof as an active ingredient, for the prevention, improvement, or treatment of symptoms or diseases selected from the group consisting of obesity due to overeating, diabetes or elevated blood glucose levels resulting from obesity due to overeating, and hepatic fat accumulation resulting from obesity due to overeating.

The present disclosure provides recombinantly manufactured fusion proteins comprising a GLP-1 protein fragment or an analog thereof linked to a feline Fc fragment. Embodiments include the administration of the fusion proteins to patients and their use as an appetite suppressant, for treatment of obesity, for prevention of obesity, or for treatment of other conditions associated with excess weight in cats. Exemplary Fc fusion proteins and pharmaceutical formulations of exemplary Fc fusion proteins are provided, in addition to methods of use and preparation.

The invention belongs to the technical field of biological medicine, and particularly relates to application of BRP polypeptide in preparation of a medicine for treating diabetes. The invention discloses application of BRP polypeptide in preparation of a medicine for treating diabetes. The amino acid sequence of the BRP polypeptide is shown as SEQ ID NO. 1. Pancreas islet and cell experiments prove that the BRP polypeptide stimulates secretion of insulin, glucagon and GLP-1 in a dose-dependent manner and is independent of an ATP-dependent potassium channel. In obese diabetic mice induced by high fat diet, the BRP polypeptide is proved to be capable of remarkably promoting secretion of insulin and GLP-1 of the mice, the BRP polypeptide has a brand-new and direct hormone stimulation application potential in the aspect of medicines for treating metabolic diseases such as diabetes and obesity, and the BRP polypeptide is different from the prior art focusing on appetite inhibition and has a wide application prospect. Therefore, a research direction is provided for developing medicines for treating metabolic diseases such as diabetes mellitus and obesity.

The application discloses a kind of guanara extract-EGCG synergistic fat-burning slimming composition, it relates to the technical field of functional food and weight management.The composition is composed of guanara extract, epigallocatechin gallate and konjac glucomannan, by limiting the weight ratio of each component and key performance parameter, using the dynamic gel network formed by konjac glucomannan, realize the in-situ physical protection and whole digestive tract programmed release of active ingredients, and build a multi-level coherent and connected appetite suppression system.The application solves the technical problems of poor stability of active ingredients, low bioavailability and fragmented appetite regulation mechanism in the prior art, can realize the deep synergy of fat-burning and food control, can be used for preparing weight management related oral solid preparations, has high safety, is suitable for industrial large-scale production and market promotion and application.

The present invention relates to new compounds having appetite-suppressing effects and their uses as a drug for treating diseases and disorders, especially metabolic syndrome. In particular, the present invention relates to compounds of general formula (I) and their uses as a drug for treating diseases and disorders, especially metabolic syndrome.

To provide an oral composition having excellent glucagon-like peptide-1 secretion promoting action and appetite suppressing action.SOLUTION: The glucagon-like peptide-1 secretion-promoting composition contains Terminalia beryllia. The appetite suppressing composition contains Terminalia beryllia.SELECTED DRAWING: None

Compositions and methods for administering ketone bodies to a subject include a ketone body or ketone body precursor complexed with or coupled to at least one amino acid. The compositions and methods cause one or more of: weight loss, weight maintenance, reduced blood glucose level, maintenance of blood glucose level, increased muscle and physical performance, enhanced metabolic and cellular repair, improved detoxification and gut health, targeted bioavailability, sustained release and controlled absorption, increased metabolic efficiency, enhanced cellular uptake, minimized side effects, multifunctional therapeutics, improved focus, improved energy, improved cognitive function, improved mental acuity, treatment of traumatic brain injury, treatment of diabetes, treatment of neurological disorder, treatment of cancer, treatment of inflammatory condition, appetite suppression, anti-aging effects, anti-glycation effects, treatment of epilepsy, treatment of depression, improved performance, improved muscle mass, improved motor function, increased strength, increased metabolism, increased fat loss, increased fat oxidation, improved body composition, and improved mood.

Disclosed herein is the use of N6-benzylaminopurine (BAP) as an appetite suppressant in animals including humans. The results of studies demonstrate the use of BAP as an appetite suppressant in animals, and the use of this common agricultural supplement for plant growth can be used to help to alleviate the ever-growing obesity pandemic afflicting modern society.

The present disclosure provides recombinantly manufactured fusion proteins comprising a GLP-1 protein fragment or an analog thereof linked to a feline Fc fragment. Embodiments include the administration of the fusion proteins to patients and their use as an appetite suppressant, for treatment of obesity, for prevention of obesity, or for treatment of other conditions associated with excess weight in cats. Exemplary Fc fusion proteins and pharmaceutical formulations of exemplary Fc fusion proteins are provided, in addition to methods of use and preparation.

The present invention relates to a spray that suppresses the user's appetite (bulimia) immediately and gives him a feeling of fullness so that he is not forced to eat a snack of any kind to deal with the feeling of hunger. The present invention contains chromium, French Lilac Extract, tyrosine, nicotinamide adenine dinucleotide (NAD), berberine, tryptophan, eggplant extract and has the flavor of vanilla, mint, banana, green apple, avocado, cinnamon and grapefruit. Its use is simple, pleasant and completed in two or three sprays into the mouth.

The invention discloses a smell-based appetite suppression method and device and intelligent wearable equipment, the method and device are used for the intelligent wearable equipment, the intelligent wearable equipment comprises a smell cabin, and the method comprises the following steps: detecting whether a user is eating or not; when the user is eating, the smell cabin is controlled to release appetite suppression smell. When the user eats food, the appetite inhibition smell is released, the user is induced to rapidly generate appetite inhibition, food intake is reduced, calorie intake is reduced, and the weight management effect is improved.

The present application relates to the technical field of polypeptide drugs for metabolic diseases, and in particular relates to a triple receptor agonist (protein) of glucagon-like peptide (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) and glucagon (GCG). The triple receptor agonist protein provided in the technical solution achieves weight loss while exhibiting lower side effects and enhancing drug compliance. The triple receptor agonist developed in the technical solution can be applied to the preparation of a drug with weight loss, lipid-lowering or blood sugar-lowering effects, solving the technical problem that existing triple receptor agonists of GLP-1, GIP and GCG are difficult to reduce side effects while reducing body weight. The drug breaks through the traditional weight loss mode of appetite suppression, has a unique mechanism of action and good safety, provides a safer and more effective treatment for patients, and has a broad market prospect and social benefit.

The invention discloses application of 2-hydroxy-3-methylbutyric acid in weight reduction and lipid reduction, and belongs to the fields of biological medicine manufacturing, biological medicine application and functional food development. The invention provides the application of the 2-hydroxy-3-methylbutyric acid and the derivative thereof in weight loss for the first time, and the compound can inhibit the weight gain of a high fat diet induced obesity model mouse, reduce body fat and reduce the fat cell area of the high fat diet induced obesity model mouse. Compared with a GLP-1 receptor weight-reducing medicine for reducing weight by inhibiting appetite, the compound 2-hydroxy-3-methylbutyric acid and the derivative thereof do not depend on appetite inhibition, and interfere and prevent obesity by accelerating fat metabolism, so that the weight-reducing effect is achieved; and side effects such as gastrointestinal discomfort and cardiovascular risk caused by appetite intervention are avoided. The invention provides a safe and effective new strategy for reducing weight and lipid.